Cardiocast

Analysis shows ‘Devil’s bargain’ in cardiac arrest


 

The “Devil’s bargain” of epinephrine use in cardiac arrest plays out in a new analysis. Also this week, updated recommendations reflect maturation of transcatheter aortic valve replacement, a comparison of cardiovascular protection in type 2 diabetes drugs, and sweeping reductions in documentation requirements headline a new Medicare fee schedule proposal. Listen on iTunes.

Recommended Reading

CANVAS: Canagliflozin cuts cardiovascular events, doubles risk of amputations
Type 2 Diabetes ICYMI
LEADER post hoc analysis: Mechanism behind liraglutide’s cardioprotective effects unclear
Type 2 Diabetes ICYMI
No increased overall cardiovascular risk seen with exenatide use
Type 2 Diabetes ICYMI
New hematologic, cardiovascular system link may have therapeutic implications
Type 2 Diabetes ICYMI
Canagliflozin falls short for primary CV prevention in T2DM
Type 2 Diabetes ICYMI
OSA may provide cardioprotection
Type 2 Diabetes ICYMI
Young diabetics are at sevenfold increased risk of sudden cardiac death
Type 2 Diabetes ICYMI
NIH cans study that relied on millions in funding from alcohol companies
Type 2 Diabetes ICYMI
Better stent technology needed for diabetes patients
Type 2 Diabetes ICYMI
Alirocumab’s benefit greater in diabetes patients: ODYSSEY Outcomes
Type 2 Diabetes ICYMI